A Novel Form of Tissue Factor and Cardiovascular Disease

一种新型组织因子与心血管疾病

基本信息

  • 批准号:
    6937225
  • 负责人:
  • 金额:
    $ 39.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-09-12 至 2007-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Tissue factor (TF) is a transmembrane glycoprotein that regulates hemostasis and is thought to play a critical role in mediating arterial thrombosis. In animal models, TF also mediates the intimal response to arterial injury and the extent of damage resulting from ischemia-reperfusion injury. TF was thought to exist as a single form whose activity was dependent upon its insertion in the cell membrane. TF has recently been found in microparticles that are present in tissues and in the circulation. In addition, an alternatively spliced form of TF (asTF) has been identified that excludes exon 5 and contains a frame shift that generates a unique C-terminus without a transmembrane domain. asTF activity requires exposure to lipids, but not insertion into a lipid bilayer. asTF has been isolated from blood and is a major component of ex vivo and in vivo thrombi. The investigators hypothesize that asTF plays critical roles in regulating arterial thrombosis, in mediating normal cardiac hemostasis, and in mediating intimal hyperplasia and the response to ischemia-reperfusion. This proposal will examine the regulation and biologic role(s) of asTF and full-length TF (flTF) in cell culture and in genetically engineered mice. Aim 1 will establish the time course of asTF expression in smooth muscle cells, macrophages, endothelial cells, and cardiocytes and determine whether alternative splicing exhibits agonist, tissue and developmental specificity. It will also determine whether, as a soluble molecule, asTF binds specifically to vascular cells and exhibits agonist properties distinct from its ability to initiate coagulation. Aim 2 will establish the role of asTF in hemostasis, thrombosis, and in TF-mediated responses to injury. Mice will be generated in which one or both forms of TF are regulated by the endogenous TF promoter. The investigators will test the hypotheses that: 1) flTF is critical for embryonic survival; 2) asTF is critical for generating significant thrombosis at sites of arterial injury; 3) asTF plays a pivotal role in regulating the intimal response to arterial injury; 4) flTF plays the dominant role in mediating normal hemostasis, but asTF is important in mediating hemostasis at the level of the myocardial capillaries; 5) asTF and flTF play complementary roles in mediating ischemia-reperfusion injury; and 6) asTF mediates normal cell functions, including growth, migration, and adhesion. These studies will provide insights into a novel form of circulating TF that may play a key role in cardiovascular disease.
描述(由申请方提供):组织因子(TF)是一种调节止血的跨膜糖蛋白,被认为在介导动脉血栓形成中起关键作用。在动物模型中,TF还介导动脉损伤的内膜反应和缺血-再灌注损伤导致的损伤程度。TF被认为以单一形式存在,其活性取决于其插入细胞膜。TF最近被发现存在于组织和循环中的微粒中。此外,已经鉴定了TF的选择性剪接形式(asTF),其不包括外显子5并且包含产生独特的C-末端而没有跨膜结构域的移码。asTF活性需要暴露于脂质,但不需要插入脂质双层。asTF已从血液中分离出来,是离体和体内血栓的主要成分。研究者推测asTF在调节动脉血栓形成、介导正常心脏止血、介导内膜增生和对缺血再灌注的反应中起关键作用。本提案将研究asTF和全长TF(flTF)在细胞培养和基因工程小鼠中的调节和生物学作用。目的1将建立平滑肌细胞、巨噬细胞、内皮细胞和心肌细胞中asTF表达的时间过程,并确定选择性剪接是否具有激动剂、组织和发育特异性。它还将确定作为可溶性分子,asTF是否特异性结合血管细胞,并表现出与其启动凝血能力不同的激动剂特性。目的2将确定asTF在止血、血栓形成和TF介导的损伤反应中的作用。将产生其中一种或两种形式的TF受内源性TF启动子调节的小鼠。研究者将检验以下假设:1)flTF对胚胎存活至关重要; 2)asTF对动脉损伤部位产生显著血栓至关重要; 3)asTF在调节动脉损伤的内膜反应中起关键作用; 4)flTF在介导正常止血中起主导作用,但asTF在介导心肌毛细血管水平止血中很重要; 5)asTF和flTF在介导缺血再灌注损伤中发挥互补作用; 6)asTF介导正常细胞功能,包括生长、迁移和粘附。这些研究将提供一种新形式的循环TF的见解,这种TF可能在心血管疾病中发挥关键作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mark B Taubman其他文献

Effect of p27 Deficiency and Rapamycin on Intimal Hyperplasia: <em>In Vivo</em> and <em>In Vitro</em> Studies Using a p27 Knockout Mouse Model
  • DOI:
    10.1038/labinvest.3780298
  • 发表时间:
    2001-06-01
  • 期刊:
  • 影响因子:
  • 作者:
    Mercè Roqué;Ernane D Reis;Carlos Cordon-Cardo;Mark B Taubman;John T Fallon;Valentin Fuster;Juan J Badimon
  • 通讯作者:
    Juan J Badimon
FAILURE OF VASCULAR SMOOTH MUSCLE CELL (VSMC) ATTACHMENT TO COLLAGEN MATRICES RESULTS IN PROLONGED GROWTH ARREST • 150
血管平滑肌细胞(VSMC)对胶原基质附着失败导致生长停滞延长 • 150
  • DOI:
    10.1203/00006450-199704001-00170
  • 发表时间:
    1997-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Andrea S Weintraub;Mark B Taubman
  • 通讯作者:
    Mark B Taubman

Mark B Taubman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mark B Taubman', 18)}}的其他基金

Smooth Muscle Cell Tissue Factor and Cardiovascular Disease
平滑肌细胞组织因子与心血管疾病
  • 批准号:
    8403981
  • 财政年份:
    2010
  • 资助金额:
    $ 39.38万
  • 项目类别:
Smooth Muscle Cell Tissue Factor and Cardiovascular Disease
平滑肌细胞组织因子与心血管疾病
  • 批准号:
    7766084
  • 财政年份:
    2010
  • 资助金额:
    $ 39.38万
  • 项目类别:
Smooth Muscle Cell Tissue Factor and Cardiovascular Disease
平滑肌细胞组织因子与心血管疾病
  • 批准号:
    8208058
  • 财政年份:
    2010
  • 资助金额:
    $ 39.38万
  • 项目类别:
Smooth Muscle Cell Tissue Factor and Cardiovascular Disease
平滑肌细胞组织因子与心血管疾病
  • 批准号:
    8010648
  • 财政年份:
    2010
  • 资助金额:
    $ 39.38万
  • 项目类别:
Regulation of mRNA Stability in Vascular smooth Muscle
血管平滑肌 mRNA 稳定性的调节
  • 批准号:
    7485123
  • 财政年份:
    2007
  • 资助金额:
    $ 39.38万
  • 项目类别:
Regulation of mRNA Stability in Vascular smooth Muscle
血管平滑肌 mRNA 稳定性的调节
  • 批准号:
    7429098
  • 财政年份:
    2006
  • 资助金额:
    $ 39.38万
  • 项目类别:
Regulation of mRNA Stability in Vascular smooth Muscle
血管平滑肌 mRNA 稳定性的调节
  • 批准号:
    7142768
  • 财政年份:
    2005
  • 资助金额:
    $ 39.38万
  • 项目类别:
Regulation of mRNA stability in vascular smooth muscle
血管平滑肌 mRNA 稳定性的调节
  • 批准号:
    6815440
  • 财政年份:
    2004
  • 资助金额:
    $ 39.38万
  • 项目类别:
Tissue factor in smooth and cardiac muscle
平滑肌和心肌中的组织因子
  • 批准号:
    6866585
  • 财政年份:
    2004
  • 资助金额:
    $ 39.38万
  • 项目类别:
A Novel Form of Tissue Factor and Cardiovascular Disease
一种新型组织因子与心血管疾病
  • 批准号:
    6602867
  • 财政年份:
    2003
  • 资助金额:
    $ 39.38万
  • 项目类别:

相似海外基金

Study on the elucidation and prevention for cardiovascular disorder by HACEK group oral bacteria
HACEK群口腔菌对心血管疾病的阐明和预防研究
  • 批准号:
    23390428
  • 财政年份:
    2011
  • 资助金额:
    $ 39.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Oxidative stress induced change of Ubiquitin modification in Mineralocorticoid receptor and cardiovascular disorder
氧化应激诱导盐皮质激素受体泛素修饰变化与心血管疾病
  • 批准号:
    20790664
  • 财政年份:
    2008
  • 资助金额:
    $ 39.38万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Lifecourse Development, Psychosocial Function & Cardiovascular Disorder
生命历程发展、心理社会功能
  • 批准号:
    6649470
  • 财政年份:
    2002
  • 资助金额:
    $ 39.38万
  • 项目类别:
Lifecourse Development, Psychosocial Function & Cardiovascular Disorder
生命历程发展、心理社会功能
  • 批准号:
    6505076
  • 财政年份:
    2001
  • 资助金额:
    $ 39.38万
  • 项目类别:
Lifecourse Development, Psychosocial Function & Cardiovascular Disorder
生命历程发展、心理社会功能
  • 批准号:
    6618935
  • 财政年份:
    2001
  • 资助金额:
    $ 39.38万
  • 项目类别:
Lifecourse Development, Psychosocial Function & Cardiovascular Disorder
生命历程发展、心理社会功能
  • 批准号:
    6358051
  • 财政年份:
    2000
  • 资助金额:
    $ 39.38万
  • 项目类别:
Lifecourse Development, Psychosocial Function & Cardiovascular Disorder
生命历程发展、心理社会功能
  • 批准号:
    6229279
  • 财政年份:
    1999
  • 资助金额:
    $ 39.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了